Search results
Showing 51 to 100 of 170 results for metastatic breast cancer
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
In development Reference number: GID-TA11773 Expected publication date: TBC
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Past technology appraisal appeals and decisions
In development Reference number: GID-TA11439 Expected publication date: TBC
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Microwave ablation for primary or metastatic cancer in the lung (HTG609)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for HTG609Show all sections
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued Reference number: GID-TAG403
Discontinued Reference number: GID-TAG387
In development Reference number: GID-TA11342 Expected publication date: TBC
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for HTG302Show all sections
Sections for HTG302
Discontinued Reference number: GID-TAG391
Discontinued Reference number: GID-TAG432
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
In development Reference number: GID-TA11687 Expected publication date: TBC
Discontinued Reference number: GID-TAG436
Discontinued Reference number: GID-TAG410
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
In development Reference number: GID-TA11400 Expected publication date: TBC
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued Reference number: GID-TAG411
In development Reference number: GID-TA11674 Expected publication date: 07 May 2026
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued Reference number: GID-TAG417
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
in combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012
Discontinued Reference number: GID-TAG404
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011
In development Reference number: GID-TA11862 Expected publication date: TBC
In development Reference number: GID-TA11535 Expected publication date: TBC
Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)
Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.
View recommendations for HTG162Show all sections
Sections for HTG162
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for HTG171Show all sections
Sections for HTG171
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
View a complete list of all our guidance, NICE advice and quality standards currently in development
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
bisphosphonate therapy:- Which groups of people with early and locally advanced breast cancer would benefit...
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Discontinued Reference number: GID-TA10803
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .